Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ovid Therapeutics Inc. - Common Stock (NQ:OVID)

0.3020 +0.0020 (+0.67%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Ovid Therapeutics Inc. - Common Stock

< Previous 1 2 Next >
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Get insights into the top gainers and losers of Friday's after-hours session.
Discover the top movers in Friday's after-hours session and stay informed about the post-market dynamics. 
Via Chartmill
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Top movers in Wednesday's after hours session
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements. 
Via Chartmill
Expert Outlook: Ovid Therapeutics Through The Eyes Of 7 Analysts
Via Benzinga
The Latest Analyst Ratings For Ovid Therapeutics
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Top movers in Wednesday's pre-market session
Discover the top movers in Wednesday's pre-market session and stay informed about market dynamics. 
Via Chartmill
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Evaluating Ovid Therapeutics: Insights From 6 Financial Analysts
Via Benzinga
Cracking The Code: Understanding Analyst Reviews For Ovid Therapeutics
Via Benzinga
OVID Stock Earnings: Ovid Therapeutics Beats EPS, Beats Revenue for Q2 2024
OVID stock results show that Ovid Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
7 Sorry Biotech Stocks Set to Make Investors Sad
Biotech stocks can be extremely challenging because it takes a long time to bring a therapy to market. Here are some biotech stocks to sell. 
Via InvestorPlace
Nasdaq Surges Over 200 Points; Aaron's Shares Jump
Via Benzinga
Is the Stock Market Closed on Juneteenth 2024?
Investors wondering if the stock market is closed on Juneteenth 2024 have come to the right place as we have an answer to that question! 
Via InvestorPlace
ACHR Stock Alert: Archer Aviation Strikes New Deal With Signature Aviation
Archer Aviation stock is down on Monday after the company alerted ACHR investors to a new MOU signed with Signature Aviation. 
Via InvestorPlace
Why Ovid Therapeutics Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
AAN Stock Alert: The Aaron’s Company Pops 33% on Take-Private Deal
The Aaron's Company stock is up on Monday after it announced a take-private deal that values AAN shares at $10.10 each. 
Via InvestorPlace
Why Is Ovid Therapeutics (OVID) Stock Down 69% Today?
Ovid Therapeutics stock is down on Monday with heavy trading of OVID shares after the company reported a failed Phase3 clinical trial. 
Via InvestorPlace
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Crude Oil Rises 1%; Mustang Bio Shares Spike Higher
Via Benzinga
US Stocks Mixed; Dow Tumbles Over 100 Points
Via Benzinga
Topics Stocks
What's Going On With Ovid Therapeutics After Takeda's Two Phase 3 Epilepsy Studies Fail?
Takeda Pharmaceutical reveals Phase 3 study data for Soticlestat (TAK-935) in treating Dravet and Lennox-Gastaut syndromes. In 2021, Ovid Therapeutics out licensed the drug. 
Via Benzinga
Why Nurix Therapeutics Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
3 Sorry Penny Stocks to Sell in May While You Still Can
Steer clear of these three penny stocks to sell that are plagued by financial instability and mounting losses. 
Via InvestorPlace
Wall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for May 2024
Although the concept of penny stocks to buy is extremely risky, these ideas have the advantage of analysts’ positive assessments. 
Via InvestorPlace
OVID Stock Earnings: Ovid Therapeutics Beats EPS, Beats Revenue for Q1 2024
OVID stock results show that Ovid Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.